Published Research

Call +1 (855) 645-2583International: +1 (866) 663-3102

Amyotrophic Laterasl Sclerosis (ALS)

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive loss of spinal cord and cortical motoneurons. The condition is sometimes called Lou Gehrig’s disease in North America, after the New York Yankees baseball player who was diagnosed with the disease in 1939. The disorder is characterized by rapidly progressive weakness, muscle atrophy and fasciculations, muscle spasticity, difficulty speaking (dysarthria), difficulty swallowing (dysphagia), and decline in breathing ability.

Stem cell therapy will include three sessions of 1x intravenous (IV) infusion and 1x intrathecal (IT) injection, spaced 5-12 days apart.  Safety assessment will include administration of adverse events questionnaires, physical exam, and blood test conducted at specified. In order to assess efficacy of therapy, muscle strength measurement and the amyotrophic lateral sclerosis functional rating scale will be conducted at specific intervals.

To find out more about how you may benefit from this stem cell research protocol, please complete our Contact Us form and one of our physicians will reach out to you for a private consultation.